Gavin Milne

Gavin Milne is a Principal Scientist at Sygnature Discovery, based in Macclesfield, UK.2 He has a strong background in medicinal chemistry and is highly educated. Milne's research focuses on drug discovery, particularly in the field of cancer treatment. He has been involved in studies on GPR65 inhibitors and their potential in transforming cancer therapy.13

Milne has authored several research works, with 6 publications and 11 citations to his name.3 His recent work includes research on PTT-4256, a first-in-class small molecule inhibitor of GPR65 that counteracts the effects of low pH in the tumor microenvironment.3

He is well-connected in his field, with 417 connections on LinkedIn.2 Milne's educational background includes studying at the University of St. Andrews.2